ABSTRACT Antischizophrenic neuroleptic drugs of the diphenylbutylpiperidine class, which includes pimozide, fluspirilene, penfluridol, and clopimozide, inhibit [3H]nitrendipine binding with IC50 values of 13-30 nM. This inhibition involves receptors for the verapamil/prenylamine class of calcium channel antagonists. These diphenylbutylpiperidines also inhibit potassium-induced calcium-dependent contractions of rat vas deferens at concentrations of 40-350 nM. Other phenothiazine and butyrophenone neuroleptics lack such potent calcium-antagonist actions. Diphenylbutylpiperidines also differ from other neuroleptics in their ability to relieve negative symptoms of schizophrenia, such as emotional withdrawal, as well as the positive symptoms which respond to all neuroleptics. We suggest that these unique antischizophrenic actions are related to a blockade by diphenylbutylpiperidines of voltage-operated calcium channels.
The neuroleptic drugs are chemically diverse compounds that share the ability to relieve schizophrenic symptoms. Their antischizophrenic actions are thought to involve blockade of dopamine receptors, since their relative potencies at D2 dopamine receptors correlate closely with clinical efficacy (1, 2) . Although the influences of various neuroleptics on the positive symptoms of schizophrenia, delusions and hallucinations, are similar, other actions vary among the drugs. Neuroleptics have various tendencies to elicit extrapyramidal parkinsonian side effects related to their various muscarinic anticholinergic actions (3, 4) . Sedating and hypotensive effects of certain neuroleptics are associated with blockade of a-1 adrenergic receptors (1, 5) .
Most neuroleptic drugs relieve the positive symptoms of schizophrenia but are less effective for the negative symptoms, such as emotional withdrawal and poverty of speech and affect (6) . One neuroleptic class, the diphenylbutylpiperidines (DPBPs), including pimozide, clopimozide, fluspirilene, and penfluridol, do ameliorate negative as well as positive schizophrenic symptoms (7) (8) (9) (10) (11) (12) (13) (14) .
Voltage-dependent calcium channels that mediate functions of smooth muscle and cardiac muscle and neural tissue are blocked by calcium channel-antagonist drugs (15, 16 (18, 19) . The DPBPs display structural similarities to verapamil-like drugs (Fig. 1) . Whereas most neuroleptics augment prolactin release from the pituitary by blocking dopamine receptors, the DPBPs can inhibit prolactin release and smooth muscle contraction, possibly by impairing calcium influx (20) (21) (22) (23) . In this paper, we report that DPBP neuroleptics are calcium channel antagonists with potencies comparable with their potencies in blocking dopamine receptors. We suggest that the unique psychoactive effects of these drugs are related to calcium channel antagonism in the brain.
MATERIALS AND METHODS
Binding assays in membranes prepared from male SpragueDawley rat (Charles River Breeding Laboratories) cerebral cortices, filtration, and liquid scintillation counting were carried out as described (17, 18 
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RESULTS
Lidoflazine allosterically modulates [3H]nitrendipine binding by competing with verapamil and related drugs at a single site (18) . Thus, the inhibition of [3H]nitrendipine binding by lidoflazine and flunarizine can be reversed by methoxyverapamil (D-600) (18) . To ascertain whether the DPBP neuroleptics act at the verapamil sites or at the dihydropyridine binding site, we explored the influence of methoxyverapamil on the inhibition of [3H]nitrendipine binding by DPBPs (Fig. 3) . Inhibition of [3H]nitrendipine binding by fluspirilene and pi. mozide (Fig. 3) Proc. Natl. Acad. Sci. USA 80 (1983) drugs act at the verapamil site but have various efficacies in allosterically reducing [3H]nitrendipine binding (18) . The calcium channel antagonist diltiazem also acts at this site but allosterically enhances [3H]nitrendipine binding (18) . To determine whether the influences of DPBPs on [3H]nitrendipine binding reflect pharmacologically relevant calcium channel blockade, we monitored drug effects on potassium-induced contractions of the rat vas deferens. Potassium depolarization elicits contractions of the rat vas deferens that are absolutely dependent on calcium. The DPBP neuroleptics block these contractions in a fashion that is reversed by higher concentrations of calcium. Schild plots indicate that these drugs compete with calcium (slopes of 0.84 for pimozide and fluspirilene) (Fig. 4) respectively. Thus, the DPBP neuroleptics are comparable with, and in some instances substantially more potent than, clinically used calcium channel-antagonist drugs (15, 16, 25) . Since the rat vas deferens does not possess dopamine receptors (26) , blockade of such sites is not related to the DPBP actions. Moreover, in the range of concentrations eliciting complete blockade of dopamine receptors (10-100 nM), other neuroleptic drugs, including phenothiazines such as chlorpromazine and butyrophenones such as haloperidol and spiperone, do not influence rat vas deferens contractions (data not shown).
DISCUSSION
The major finding of the present study is that DPBP neuroleptic drugs are potent calcium channel antagonists. These influences on voltage-sensitive calcium channels are apparent both in receptor binding studies and in blocking calcium-dependent smooth muscle contractions. The reversal by methoxyverapamil of the inhibition of [3H]nitrendipine binding indicates that the DPBPs act at the same site as verapamil-like drugs. Our findings on the effects on rat vas deferens contractions substantiate earlier observations that DPBP neuroleptics antagonize calcium-dependent contractions of rat caudal artery and guinea pig taenia caeci (20, 23) . Although neuroleptics including DPBPs bind to calmodulin, such effects cannot explain the effects on smooth muscle as the potencies are 1-2% of those of DPBPs at calcium channels (27) .
The similar potencies of DPBPs at calcium channel-antagonist binding sites and dopamine receptors (Table 1) indicate that at therapeutic doses these drugs will influence calcium channels. Moreover, in animals, doses that are therapeutic in man provide brain concentrations sufficient to occupy 50% of calcium channel-antagonist binding sites (28) . Accordingly, behavioral alterations related to calcium channel modulation should occur following treatment with therapeutic doses of DPBP neuroleptics but not neuroleptics lacking calcium channel-antagonist actions. While all neuroleptics relieve the positive symptoms of schizophrenia, some clinical actions appear unique to DPBPs. DPBPs are substantially more effective than other neuroleptics in reversing emotional withdrawal and poverty of affect and speech, the negative schizophrenic symptoms (6) (7) (8) (9) (10) (11) (12) (13) (14) . Such effects have been reported consistently in independent studies of DPBPs such as pimozide (7) (8) (9) (10) , penfluridol (11, 12) , and fluspirilene (13, 14) . In several studies, these actions were reported as unique for the DPBPs when compared in the same study with neuroleptics of other chemical classes (8, 9, 11, 13) . We suggest that this selective effect of DPBPs on schizophrenic negative symptoms derives from calcium channel influences.
How the affected calcium channels modulate schizophrenic behavior is unclear. Conceivably, the relief of negative symptoms by DPBPs may be related to the stimulant side effects, such as insomnia and nervousness, observed with these drugs (7, 11, 13) .
Cardiovascular side effects related to calcium antagonism have not been described with the DPBP neuroleptics, perhaps because the high partitioning of the drug into the brain keeps peripheral levels relatively low. Alternatively, these drugs may show relative specificity for neuronal calcium channels. One would expect that combined administration of DPBPs with calcium channel-antagonist drugs used for cardiovascular therapy may elicit synergistic effects.
The unique clinical spectrum of DPBP antischizophrenic actions suggests that voltage-dependent calcium channel activity in the brain may influence behavior along an activation continuum. Conceivably, centrally acting calcium channel-antagonist drugs that influence the verapamil site will have therapeutic utility independent of dopamine receptor blockade.
